Related Experiment Video
Updated: Jun 16, 2025
Cannula Implantation into the Cisterna Magna of Rodents
Published on: May 23, 2018
Treatment of CACNA1A Encephalopathy and Cerebral Edema with Magnesium and Dexamethasone
Cailey Turner1, Lauren Campbell2, Ryan Fung3
1Postgraduate Medical Education Program, Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada.
Insights
Pathogenic CACNA1A mutations cause severe neurological symptoms. Intravenous magnesium sulfate and dexamethasone showed successful treatment for two patients with CACNA1A-associated encephalopathy, hemiplegia, and cerebral edema.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- CACNA1A gene mutations are linked to severe neurological disorders.
- CACNA1A-associated encephalopathy presents with hemiplegia and cerebral edema.
- Limited established treatment protocols exist for this condition.
Purpose of the Study:
- To report successful treatment outcomes in patients with CACNA1A-associated encephalopathy, hemiplegia, and cerebral edema.
- To suggest potential therapeutic agents for managing this rare neurological disorder.
Main Methods:
- Case report of two patients with confirmed CACNA1A mutations.
- Treatment administration included intravenous magnesium sulfate and dexamethasone.
- Clinical evaluation and symptom monitoring post-treatment.
Main Results:
- Both patients experienced successful resolution of encephalopathy, hemiplegia, and cerebral edema.
- One patient also met diagnostic criteria for familial hemiplegic migraine.
- Treatment with magnesium and dexamethasone appeared effective despite protocol variations.
Conclusions:
- Intravenous magnesium sulfate and dexamethasone may be effective in managing CACNA1A-associated encephalopathy, hemiplegia, and cerebral edema.
- These agents could form a basis for future treatment algorithms.
- Further research is required to optimize dosage and duration of therapy.
Abstract:
Pathogenic CACNA1A mutations can result in paroxysmal attacks of encephalopathy, hemiplegia and cerebral edema. We report two patients with CACNA1A-associated encephalopathy, hemiplegia and contralateral hemispheric cerebral edema treated successfully with intravenous magnesium sulfate and dexamethasone. One patient met the clinical criteria for familial hemiplegic migraine. There is a paucity of guidance in the literature on how to manage these patients. Despite some discrepancies in the treatment protocols in our two cases, they indicate that magnesium and dexamethasone could be part of the treatment algorithm for these patients. Further research to delineate appropriate dosing and duration of therapy is needed.
More Related Videos
05:52Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
06:54A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
